Loading...
XKRX
058820
Market cap80mUSD
Jul 09, Last price  
872.00KRW
1D
-2.90%
1Q
-50.82%
Jan 2017
-72.58%
IPO
-38.59%
Name

CMG Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:058820 chart
P/E
—
P/S
1.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
38.93%
Rev. gr., 5y
10.30%
Revenues
105.23b
+6.19%
2,731,224,0003,214,591,0004,108,269,0004,501,223,0003,904,384,0004,476,412,0004,864,985,00050,741,945,00064,459,891,27069,475,496,00082,197,410,00093,906,675,00099,099,733,000105,229,185,000
Net income
-8.96b
L
278,000,000327,438,000445,374,000475,602,00022,938,000176,253,000176,553,0002,641,002,000214,996,4903,165,485,000-388,140,0006,455,349,0002,694,712,000-8,963,047,000
CFO
-11.02b
L
419,963,000-3,731,185,000664,125,0002,049,079,0001,913,063,0001,825,982,000796,574,0002,443,834,000663,847,0001,282,081,0004,937,550,0003,909,002,000290,089,000-11,020,198,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Based in Seoul, South Korea, CMG Pharmaceutical Co., Ltd. operates as a pharmaceutical firm dedicated to the research, development, and sale of innovative oral thin film (OTF) medications. Its diverse product portfolio features OTF formulations such as Tadalafil for addressing erectile dysfunction, Entecavir for managing hepatitis B, Aripiprazole for treating schizophrenia, and Montelukast for alleviating asthma and allergic rhinitis. The company also engages in a strategic partnership with Handok Inc., focusing on advancements in cancer treatment. Established in 2001, the enterprise was formerly recognized as Skynewpharm Co Ltd before officially becoming CMG Pharmaceutical Co., Ltd. in April 2013.
URL
http://cmgpharma.co.kr/
IPO date
Aug 31, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT